Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Δ32/Δ32.
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.
Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Limited cross-border infections in patients newly diagnosed with HIV in Europe.
No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.
Update of the drug resistance mutations in HIV-1: March 2013.
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.